• Figyelem!

  A megtekinteni kívánt tartalom inaktív.

  CNS gyógyszereket akkreditáló Bizottság közleménye
  [2013.03.18.] - MPT Web-szerkesztőség - Hírkategória: Általános
  Dear Colleague,
  New EACIC e-learning activities are now available online on www.eacic.eu
  
  Register to our new e-learning activities, learn the best on new exciting advances in Psychiatry and Psychopharmacology and share expert opinions
  
  You can also access the program by clicking on the following links
  
  The Role of Circadian Rhythms in the Treatment of Depression 
  
  Depression and circadian rhythms
  Editoral comments by Prof G. Hajak (Germany)
  
  Mechanism of action of agomelatine
  Editoral comments by Prof G. Racagni (Italy)
  
  Clinical studies and evidence based data on agomelatine
  Editoral comments by Prof G. Goodwin (United Kingdom)
  
  Adapted from educational material developed by Professor Stephen M. Stahl and Arbor Scientia University of California, San Diego and University of Cambridge, UK 2012
  
  The past, present and future treatment of patients with schizophrenia – how far have we come?
  
  The effect of antipsychotic medication on brain structure in schizophrenia
  S. Frangou (United Kingdom)
  
  Translating the evidence on the clinical benefits of antipsychotics for routine practice
  S Leucht (Germany)
  
  Pharmacological and non-pharmacological therapies as integral components in optimizing patient outcomes
  A Schreiner (Germany)
  
  Editorial comments by Prof E. Constant (Belgium) and Dr D. Souery (Belgium)
  
  A new chapter in the history of depression
  
  Neural correlates of emotion processing: from emotional to social brain
  P. Fossati (France)
  
  The relation between mood, cognition and psychosocial functioning in psychiatric disorders
  D. V. Iosifescu (USA)
  
  A dimensional approach to antidepressant response: implication of agomelatine
  S. H. Kennedy (Canada)
  
  Onset, time course and trajectories of improvement with antidepressants 
  R. W. Lam (Canada)
  
  Patient perception of antidepressant efficacy
  P-M Llorca (France)
  
  Effective long term treatment of schizophrenia: are we there yet?
  
  How can we help our schizophrenia patients adhere to their medication? :
  Dr R Emsley (South Africa)
  
  How often and for how long should patients with schizophrenia be treated? :
  Dr PM Llorca (France)
  
  What role do LAIs have in the treatment of schizophrenia?:
  Dr A Schreiner (Germany)
  
  Editorial comments by Pr J Mendlewicz (Belgium) & Dr D Souery (Belgium)
  
  Understanding the complex interactions in GAD: from laboratory to the clinic
  
  The Role of Neuroimaging in Anxiety Disorders:
  Dr David J. Nutt (United Kingdom)
  
  Anxiety and Pain Perception: Shared Neurobiology and Influence on Patient Outcomes:
  Dr Rakesh Jain (USA)
  
  Neurobiology and Psychopharmacology of Generalised Anxiety Disorder:
  Dr Johan A. Den Boer (The Netherlands)
  
  Editorial comments by Pr J Mendlewicz (Belgium) & Pr W Pitchot (Belgium)
  
  
  This e-learning activity is free of charge and gives you the possibility to participate to the program from your office or home and get your CME credits. 
  It is easy and fast. Just complete the evaluation form and Q&A at the end of each program.
  
  Dr Daniel Souery
  

Vissza